Sichuan Biokin Pharmaceutical

Sichuan Biokin Pharmaceutical Co., Ltd., also known by the Chinese name Baili Tianteng and the shorter name Biokin, is a Chinese pharmaceutical and biopharmaceutical company headquartered in Chengdu, Sichuan. The company began operations in 1996, initially concentrating on complex generic medicines and traditional Chinese medicine products. Its early commercial business provided the revenue base for a later shift toward research-driven pharmaceutical development. In 2010, Biokin changed its strategic emphasis and began directing greater resources toward innovative medicines, particularly specialized therapies for cancer. This transition made research and development, rather than established generic and traditional-medicine products alone, central to the company’s long-term positioning. The company’s oncology ambitions include antibody-based and other advanced drug-development programs, with its wholly owned subsidiary SystImmune serving as an important vehicle for innovative biologic research and international partnering. Biokin completed an initial public offering in early 2023 and became a listed company on the Shanghai Stock Exchange STAR Market. The listing gave the company access to public capital markets and increased its visibility as a Chinese developer of innovative medicines. It also placed Biokin within the segment of Chinese pharmaceutical companies seeking to move from domestic commercial operations toward globally relevant research and licensing activities. A major turning point came in December 2023, when SystImmune and Bristol Myers Squibb entered into an agreement concerning rights to co-develop and commercialize an experimental medicine for lung and breast cancers. The arrangement could provide SystImmune with as much as US$8.4 billion, including an US$800 million upfront payment and up to US$500 million in contingent near-term payments. The agreement demonstrated the potential commercial value of Biokin’s research portfolio and connected the company with a major international pharmaceutical partner. The referenced material does not identify the experimental medicine by name, so it is not specified here. In July 2024, Biokin filed for a secondary listing on the Hong Kong Stock Exchange. The proposed listing indicated an interest in broadening its investor base and strengthening access to international capital. In November 2025, the company said that the Hong Kong listing would be delayed because of market conditions. The available reference material does not state whether the proposed listing was ultimately completed. Biokin’s business identity therefore combines a domestic pharmaceutical manufacturing heritage with an increasingly innovation-led and oncology-oriented development strategy. Its known activities span pharmaceutical production, drug research, clinical and regulatory development, and licensing or co-development partnerships. Detailed information about its full commercial product portfolio, current executives, individual development programs, and operating performance is not established by the supplied reference material.

Sichuan Biokin Pharmaceutical began in 1996 as a producer of complex generic drugs and traditional Chinese medicines. During this first phase, the company’s activities were centered on established pharmaceutical manufacturing and commercial products rather than primarily on novel drug discovery. The income generated by these businesses later supported a strategic transformation. In 2010, Biokin pivoted toward innovative drug development. The company used its existing pharmaceutical revenue to fund research into specialized cancer therapies, gradually giving research and development a more prominent role in its corporate strategy. This change reflected a broader ambition to build proprietary medicines and compete in areas where differentiated clinical value and intellectual property could produce greater long-term potential than conventional generic products alone. Biokin’s innovation strategy included work conducted through its wholly owned subsidiary SystImmune. The subsidiary became especially significant in connection with advanced oncology programs and later international partnering. The available reference material does not provide a complete chronology of SystImmune’s formation, its full pipeline, or the clinical stages of its individual candidates, so those details are not expanded here. In early 2023, Biokin completed an initial public offering and joined the Shanghai Stock Exchange STAR Market. The public listing marked an important corporate milestone: it provided access to public equity financing and established Biokin as a listed Chinese biopharmaceutical company. The STAR Market listing also aligned with the company’s innovation-oriented identity, although the supplied material does not provide offering size, listing price, ticker, or detailed financial results. The company received substantial international attention in December 2023. SystImmune and Bristol Myers Squibb agreed on a collaboration involving the co-development and commercialization of an experimental medicine for lung and breast cancers. The agreement could be worth up to US$8.4 billion to SystImmune. Its reported structure included an US$800 million upfront payment and up to US$500 million in contingent near-term payments, with the remainder dependent on future development, regulatory, and commercial outcomes. The available source does not identify the medicine by name or provide detailed terms concerning territories, milestones, royalties, or trial results. In July 2024, Biokin filed for a secondary listing on the Hong Kong Stock Exchange. A Hong Kong listing would have offered an additional route to capital and potentially expanded access to international investors, alongside the company’s existing Shanghai listing. In November 2025, Biokin said that the proposed listing would be delayed because of market conditions. The supplied reference does not indicate that the application was withdrawn permanently or that a later listing occurred. Biokin’s history is consequently characterized by three broad phases: an initial period based on generic and traditional-medicine production; a 2010 strategic shift toward innovative oncology research; and a more recent phase involving public-market access and international commercialization partnerships. Its evolution illustrates the company’s effort to use an established pharmaceutical base to support higher-risk, potentially higher-value biopharmaceutical development. Information available in the supplied sources is insufficient to document a complete product history, executive succession, detailed financial trajectory, or the ultimate regulatory status of its partnered oncology programs.

• 2025

  Hong Kong listing delayed

  [1]Sichuan Biokin Pharmaceuticalen.wikipedia.org

  The company states that its proposed Hong Kong listing will be delayed because of market conditions.

• 2024

  Hong Kong secondary-listing application

  [1]Sichuan Biokin Pharmaceuticalen.wikipedia.org

  Biokin files for a secondary listing on the Hong Kong Stock Exchange.

• 2023

  Initial public offering on the Shanghai STAR Market

  [1]Sichuan Biokin Pharmaceuticalen.wikipedia.org

  Biokin completes its initial public offering and becomes listed on the Shanghai Stock Exchange STAR Market.

• 2023

  International oncology partnership with Bristol Myers Squibb

  [1]Sichuan Biokin Pharmaceuticalen.wikipedia.org

  Wholly owned subsidiary SystImmune enters an agreement with Bristol Myers Squibb covering an experimental medicine for lung and breast cancers, with potential consideration of up to US$8.4 billion.

• 2010

  Strategic shift toward innovative medicines

  [1]Sichuan Biokin Pharmaceuticalen.wikipedia.org

  The company redirects a greater share of its strategy and resources toward innovative drug research, with particular emphasis on specialized cancer therapies.

• 1996

  Company begins pharmaceutical operations

  [1]Sichuan Biokin Pharmaceuticalen.wikipedia.org

  Biokin starts as a producer of complex generic drugs and traditional Chinese medicines.

A Chinese pharmaceutical company transitioning from established generic and traditional-medicine products toward innovative, oncology-focused biopharmaceutical research and international partnerships.

• Generic pharmaceuticals · 1996

  Complex generic medicines

  Complex generic medicines formed part of Biokin’s original business after the company began operations in 1996. These products provided an established commercial base and generated revenue that the company later used to support its shift toward innovative drug research. The supplied reference material does not identify individual generic products, therapeutic classes, or current sales status.

• Traditional Chinese medicine · 1996

  Traditional Chinese medicine products

  Traditional Chinese medicine products were another part of Biokin’s original pharmaceutical portfolio. They belong to the company’s early manufacturing and commercial history, before its strategic emphasis moved toward innovative medicines and oncology research. No specific formulations, indications, brands, or present-day portfolio status are identified in the supplied sources.

• Innovative oncology biopharmaceutical

  Experimental oncology medicine developed through SystImmune

  An experimental medicine developed through Biokin’s wholly owned subsidiary SystImmune became the subject of a December 2023 agreement with Bristol Myers Squibb. The agreement concerned co-development and commercialization for lung and breast cancer indications. The supplied reference does not state the medicine’s name, development stage, mechanism, clinical results, approval status, or commercial launch date.

• 2024

  Pursuit of a secondary Hong Kong listingStrategy

  Background

  After becoming listed on the Shanghai STAR Market, Biokin sought an additional public-market venue and broader access to investors.

  Action taken

  The company filed for a secondary listing on the Hong Kong Stock Exchange in July 2024.

  Aftermath

  In November 2025, Biokin said the proposed listing would be delayed because of market conditions. The supplied reference does not confirm whether the listing was later completed.

  Source

• 2023

  SystImmune partners with Bristol Myers SquibbM&A

  Background

  Biokin’s wholly owned subsidiary SystImmune had an experimental medicine intended for lung and breast cancer development and commercialization.

  Action taken

  SystImmune and Bristol Myers Squibb entered an agreement for co-development and commercialization rights. The reported potential value was up to US$8.4 billion, including an US$800 million upfront payment and up to US$500 million in contingent near-term payments.

  Aftermath

  The agreement increased the international visibility of Biokin’s oncology pipeline and created a potential path to development and commercialization with a major global pharmaceutical company. The supplied material does not report later clinical, regulatory, or commercial outcomes.

  Potential agreement value. Up to US$8.4 billion; includes US$800 million upfront and up to US$500 million in contingent near-term payments (Agreement announced December 2023)

  Source

• 2010

  Pivot toward innovative oncology medicinesStrategy

  Background

  Biokin had begun as a producer of complex generics and traditional Chinese medicines. It chose to use revenue from those established activities to support research into specialized cancer therapies.

  Action taken

  The company shifted strategic emphasis toward innovative drug research and development, particularly in oncology.

  Aftermath

  The shift established the innovation-led and oncology-oriented direction that later supported the company’s public listing and international licensing activity.

  Source

1. 1Sichuan Biokin Pharmaceuticalen.wikipedia.org